# European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

> **NCT02813135** · PHASE1,PHASE2 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 472 (estimated)

## Conditions studied

- Pediatric Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Topotecan
- **DRUG:** Temozolomide
- **DRUG:** Everolimus
- **DRUG:** Adavosertib
- **DRUG:** Carboplatin
- **DRUG:** Olaparib
- **DRUG:** Irinotecan
- **DRUG:** Vistusertib
- **DRUG:** Nivolumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Selumetinib
- **DRUG:** Enasidenib
- **DRUG:** Lirilumab
- **DRUG:** Fadraciclib
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Ceralasertib
- **DRUG:** Futibatinib
- **DRUG:** Capmatinib

## Key facts

- **NCT ID:** NCT02813135
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-08-03
- **Primary completion:** 2031-02
- **Final completion:** 2031-02
- **Target enrollment:** 472 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02813135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02813135, "European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02813135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*